Business

Roche takes aim at inflammatory bowel disease

With its oncology drugs in decline and a string of recent failures on Alzheimer's, the Swiss giant veers into Inflammatory Bowel Diseases (IBD) by securing for more than 7 billion the U.S. rights to an investigational new drug.

Sanofi’s strategic turnaround

The French company has announced the spin-off of its consumer unit and increased investment in the development of new immunology and inflammation drugs, but must abandon its profit targets for the next two years

BIODRUGS & ATMP

ONE HEALTH

DARWIN EU: towards easy and secure access to health data

DARWIN EU, acronym for Data Analysis and Real World Interrogation Network, is the new long-term project of EMA, the European Medicines Agency. The objective...

Novel foods that divide

spot_img
spot_img
spot_img
spot_img
spot_img
spot_img
spot_img